Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

In patients with type 2 diabetes, the risk for chronic kidney disease differed among users of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea.

Type 2 diabetes mellitus (T2DM) is a major public health challenge in India, with an estimated 101 million individuals ...

Initiation of the Phase 2 EMPOWER trial of ARD-201 for the treatment of obesity and obesity-related conditions as a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor is ...

School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, P. R. China ...

Channel 4's online TV service - now renamed Channel 4 Streaming but it's shortened to C4 – allows you to catch-up on programmes, stream live channels and dip into the archives to watch older shows, ...

The Witcher 4 has now been officially revealed, with a new trailer confirming that the game will focus on Ciri as the main protagonist. This latest look does give us an idea as to the overall ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...

and active COPD compared with dipeptidyl peptidase-4 inhibitors (DPP-4is). The study analysed data from three major USA insurance claims databases between 2013–2023. Using a propensity score–matched ...